---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-016210"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:15:32.462443+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lipocine LPCN 1154 Phase 3 PPD trial: 1/3 randomized; topline 2Q26; DSMB review 4Q25

## Summary
- One-third of planned patients randomized in LPCN 1154 Phase 3 trial for postpartum depression.
- Topline results expected in second quarter 2026.
- Independent DSMB safety review planned for fourth quarter 2025; update post-DSMB.
- Trial conducted entirely outpatient; no medical monitoring by HCP required per FDA feedback.
- CEO Mahesh Patel states LPCN 1154 can become standard of care; 505(b)(2) NDA submission targeted in 2026.

## SEC filing metadata
- accession: 0001493152-25-016210
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225016210/0001493152-25-016210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225016210/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-016210
- JSON: https://secwatch.observer/filing/0001493152-25-016210.json
- Plain text: https://secwatch.observer/filing/0001493152-25-016210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.